MARKET

GNPX

GNPX

Genprex Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5048
+0.0060
+1.20%
Closed 16:34 10/14 EDT
OPEN
0.4758
PREV CLOSE
0.4988
HIGH
0.5223
LOW
0.4501
VOLUME
104.69K
TURNOVER
--
52 WEEK HIGH
2.260
52 WEEK LOW
0.4300
MARKET CAP
7.84M
P/E (TTM)
-0.6701
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of GNPX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

GNPX News

  • The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout
  • Benzinga.3d ago
  • Genprex to Present at the MicroCap Rodeo Investor Conference
  • Business Wire.5d ago
  • Genprexs Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support
  • Business Wire.10/07 13:00
  • The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data
  • Benzinga.10/02 11:17

More

Industry

Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.09%

Hot Stocks

Name
Price
%Change

About GNPX

Genprex, Inc. is a clinical stage gene therapy company. The Company is focused on developing cancer-based upon its novel proprietary technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. The Company’s Oncoprex is lead product candidate, is the subject of an ongoing Phase I/II clinical trials at The University of Texas MD Anderson Cancer Center in patients with late stage non-small cell lung cancer, or NSCLC. Oncoprex gene therapy platform may also be effective with respect to other types of cancer, including breast, head and neck, renal cell (kidney), soft tissue cancer. The Company’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles. The Company’s Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis.
More

Webull offers Genprex Inc (GNPX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.